NCT06706219 2026-04-03
Efficacy and Safety of Sacituzumab Tirumotecan (SKB264) in Combination With Toripalimab in Patients With Initially Unresectable Stage III NSCLC
Hunan Province Tumor Hospital
Phase 2 Not yet recruiting
Clinical Trials
60 trialsNCT07493980 2026-03-27
Study on the Efficacy and Safety of JSKN016 as Neoadjuvant Therapy in Resectable Stage II-III Non-small Cell Lung Cancer Patients
Shanghai Pulmonary Hospital, Shanghai, China
Phase 2 Not yet recruiting
NCT05798845 2026-03-11
The Effect of Toripalimab Plus Radiotherapy in Patients With Operable Stage II-IIIA (N+) Non Small Cell Lung Cancer
Shanghai Chest Hospital
Phase 2 Recruiting
NCT06719700 2026-03-03
Concurrent Chemoradiotherapy Combined With Toripalimab and Surufatinib in the Treatment of Limited-Stage Small Cell Lung Cancer
Sun Yat-sen University
Phase 2 Recruiting
NCT05888402 2026-02-27
InTRist
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2 Active not recruiting
NCT04418648 2026-02-04
Study of Toripalimab for Limited-Stage Small Cell Lung Cancer Following Concurrent Chemoradiotherapy
Sun Yat-sen University
Phase 2 Terminated
NCT06984588 2026-01-30
A Study to Compare Uliledlimab Combined With Toripalimab, Toripalimab Monotherapy, and Pembrolizumab Monotherapy in Patients With Previously Untreated Locally Advanced Unresectable or Metastatic PD-L1- and CD73- Selected Non-Small Cell Lung Cancer
TJ Biopharma Co., Ltd.
Phase 2/3 Active not recruiting
NCT07376499 2026-01-29
Prospective, Single-arm, Phase II Clinical Study of Irinotecan Hydrochloride Liposome Injection Combined With Platinum and Immune Checkpoint Inhibitors Combined With Anlotinib for the Maintenance of Extensive Small Cell Lung Cancer After First-line Induction
China Medical University, China
Phase 2 Not yet recruiting
NCT07358689 2026-01-22
Toripalimab Combined With Platinum-based Chemotherapy With or Without H1 Receptor Antagonist in the Perioperative Treatment of Resectable Non-small Cell Lung Cancer
Tianjin Medical University Cancer Institute and Hospital
Phase 2 Not yet recruiting
NCT07309276 2025-12-30
A Phase II Clinical Study Evaluating the Combination Therapy of JS212 in Patients With Advanced Lung Cancer
Shanghai Junshi Bioscience Co., Ltd.
Phase 2 Not yet recruiting
NCT06293690 2025-12-18
Toripalimab Combined With SBRT for NSCLC
Shanghai Pulmonary Hospital, Shanghai, China
Phase 2 Active not recruiting
NCT07286942 2025-12-16
Stereotactic Body Radiotherapy With Sequential Iparomlimab and Tuvonralimab (QL1706) + Chemotherapy as Neoadjuvant Therapy in Patients With Resectable Non-small-cell Lung Cancer in China (LUNG-Nanjing01): a Single-arm, Single-centre, Phase 2 Trial
Jiangsu Cancer Institute & Hospital
Phase 2 Not yet recruiting
NCT05664971 2025-12-02
JS004 Combined With Toripalimab and With Standard Chemotherapy Treat Patients With Advanced Lung Cancer
Shanghai Junshi Bioscience Co., Ltd.
Phase 1/2 Completed
NCT07251582 2025-11-26
LungTime-C02
Hunan Province Tumor Hospital
Phase 3 Recruiting
NCT04374877 2025-11-10
Study of CHS-388 (Formerly Known as SRF388) in Patients With Advanced Solid Tumors
Coherus Oncology, Inc.
Phase 1 Completed
NCT05386888 2025-10-02
A Trial of GFH018 and Toripalimab in Combination With Concurrent Chemoradiotherapy in Stage III NSCLC Chemoradiotherapy in Stage III NSCLC
Genfleet Therapeutics (Shanghai) Inc.
Phase 2 Completed
NCT06623136 2025-09-26
A Study of ES102 in Combination With Toripalimab in Subjects With Advanced Non-small Cell Lung Cancer
Elpiscience Biopharma, Ltd.
Phase 2 Recruiting
NCT07169994 2025-09-12
A Study of YL202 in Combination With Other Anti-tumor Therapies in Patients With Advanced Solid Tumors
MediLink Therapeutics (Suzhou) Co., Ltd.
Phase 1/2 Recruiting
NCT06127303 2025-09-05
Toripalimab Combined With Cryoablation for First-line Oligo-progression in Driver-negative Advanced NSCLC
Shanghai Chest Hospital
Phase 2 Recruiting
NCT07039656 2025-08-07
Toripalimab Combined With Chemotherapy as Adjuvant Therapy for Non-small Cell Lung Cancer With or Without Prior Neoadjuvant Therapy
Guangdong Provincial People's Hospital
Phase 2 Recruiting
NCT07097948 2025-08-01
Adjuvant
Shanghai Pulmonary Hospital, Shanghai, China
Phase 2 Not yet recruiting
NCT05757492 2025-05-01
Study to Evaluate Safety and PK of CHS-006 in Combination With Toripalimab in Patients With Advanced Solid Tumors
Coherus Oncology, Inc.
Phase 1 Terminated
NCT06437977 2025-03-13
neoR-TORCH
Shanghai Chest Hospital
Phase 3 Recruiting
NCT05000684 2025-02-20
Study of JS004 Combined With Toripalimab for Advanced Lung Cancer
Shanghai Junshi Bioscience Co., Ltd.
Phase 1/2 Completed
NCT06732258 2024-12-27
Low-dose Radiotherapy Combined with Concurrent Chemotherapy, Toripalimab and Tifcemalimab in the Treatment of ES-SCLC
Sichuan University
Phase 1 Not yet recruiting
NCT03623776 2024-12-06
NAJSCR
Sun Yat-sen University
Phase 2 Withdrawn
NCT06709274 2024-11-29
MOTION-NSCLC
Guangdong Association of Clinical Trials
Phase NA Not yet recruiting
NCT06269211 2024-11-18
TOPLINE
Ruijin Hospital
Phase 2 Recruiting
NCT06648200 2024-10-18
Toripalimab and JS004 Combined With Platinum-based Chemotherapy for Relapsed and Extensive-stage Small Cell Lung Cancer
Shanghai Pulmonary Hospital, Shanghai, China
Phase 2 Not yet recruiting
NCT04144608 2024-08-09
TOGATHER
Hunan Province Tumor Hospital
Phase 2 Completed
NCT06095583 2024-06-21
Phase 3 Study of Toripalimab Alone or in Combination With Tifcemalimab as Consolidation Therapy in Patients With Limited-stage Small Cell Lung Cancer (LS-SCLC)
Shanghai Junshi Bioscience Co., Ltd.
Phase 3 Recruiting
NCT06256237 2024-05-29
Neoadjuvant Therapy With Toripalimab and JS004 Combined With Etoposide and Platinum Chemotherapy for Limited-stage Small Cell Lung Cancer : A Phase 2 Trial
Shanghai Pulmonary Hospital, Shanghai, China
Phase 2 Recruiting
NCT05955105 2024-05-21
A Study of ILB2109 and Toripalimab in Patients With Advanced Solid Malignancies
Innolake Biopharm
Phase 1/2 Recruiting
NCT04238169 2024-02-28
Clinical Trial Assessing the Efficacy of Abscopal Effect Induced by SBRT and Immunotherapy in Advanced NSCLC
Xinqiao Hospital of Chongqing
Phase 2 Completed
NCT04137900 2024-02-05
Safety, Tolerability and Pharmacokinetics of a Monoclonal Antibody Specific to B-and T-Lymphocyte Attenuator (BTLA) as Monotherapy and in Combination With an Anti-PD1 Monoclonal Antibody for Injection in Subjects With Advanced Malignancies
TopAlliance Biosciences
Phase 1 Unknown
NCT06208033 2024-01-17
SMET12 and Toripalimab Combined Chemotherapy in Patients With EGFR Positive Advanced Non-small Cell Lung Cancer (NSCLC)
Fujian Cancer Hospital
Phase EARLY_PHASE1 Unknown
NCT06065813 2023-10-04
Neoadjuvant Triprizumab and Radiotherapy in Operable Patients With Stage IIA-IIIA Non-small Cell Lung Cancer
Northern Jiangsu People's Hospital
Phase 2 Recruiting
NCT05962021 2023-08-01
Neoadjuvant Toripalimab for Non-squamous NSCLC With EGFR Mutation
Peking University People's Hospital
Phase 2 Not yet recruiting
NCT05798533 2023-07-10
Neo-T in Treating Patients With Advanced Solid Tumors(GI-NeoT-03)
BGI, China
Phase 1 Unknown
NCT05891080 2023-06-06
Neoadjuvant Therapy With Toripalimab and JS004 Combined With Platinum-based Doublet Chemotherapy for Resectable or Potentially Resectable Stage III Non-small Cell Lung Cancer: A Randomised Controlled, Open-label, Phase 2 Trial
Shanghai Pulmonary Hospital, Shanghai, China
Phase 2 Not yet recruiting
NCT05842018 2023-05-03
Toripalimab in Combination With Chemotherapy and Antiangiogenic Agents in Patients With Non-Small Cell Lung Cancer After Failure of Immunotherapy (PD-1/L1 Inhibitors)
Tianjin Medical University Cancer Institute and Hospital
Phase 2 Unknown
NCT05800340 2023-04-05
Neoadjuvant Immunotherapy in Rare Mutations Localized NSCLC
Guangdong Provincial People's Hospital
Phase 2 Recruiting
NCT03732664 2023-03-24
ICIs Neoadjuvant Therapy in Resectable Non-Small-Cell Lung Cancer
Second Affiliated Hospital, School of Medicine, Zhejiang University
Phase 1 Completed
NCT05212922 2023-03-20
YH001
Eucure (Beijing) Biopharma Co., Ltd
Phase 2 Withdrawn
NCT03856411 2023-02-01
A Study to Evaluate the Efficacy and Safety of Toripalimab or Placebo Combined With Chemotherapy in Treatment-naive Advanced NSCLC
Shanghai Junshi Bioscience Co., Ltd.
Phase 3 Completed
NCT05162196 2022-05-02
The Efficacy and Safety of Radiotherapy Plus Niraparib and Toripalimab in Patients With Recurrent Small Cell Lung Cancer
Wuhan University
Phase 2 Unknown
NCT05055583 2021-09-24
Toripalimab in Combination With Platinum-based Chemotherapy for Mutation-negative Stage IV Oligometastatic NSCLC
Tang-Du Hospital
Phase 2 Unknown
NCT04304248 2021-05-06
NeoTAP01
Sun Yat-sen University
Phase 2 Active not recruiting
NCT04725448 2021-04-06
Toripalimab Combined With Bevacizumab, Nab-paclitaxel and Carboplatin for Untreated Metastatic Pulmonary Sarcomatoid Carcinoma
Sichuan Cancer Hospital and Research Institute
Phase 2 Unknown
NCT04797702 2021-03-15
CT32
Shanghai Junshi Bioscience Co., Ltd.
Phase 1/2 Unknown